ProQR Therapeutics (PRQR) Accumulated Expenses (2014 - 2022)

ProQR Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $8.9 million in Q4 2022.

• Quarterly Accumulated Expenses fell 28.0% year-over-year to $8.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $8.9 million (down 28.0% YoY) and the FY2022 annual result came in at $8.9 million, down 30.4% from the prior year.
• Accumulated Expenses fell to $8.9 million in Q4 2022 per PRQR's latest filing, from $12.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.3 million in Q4 2021 and troughed at $7.3 million in Q4 2020.
• A 5-year average of $9.3 million and a median of $8.9 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses jumped 68.75% in 2021, then dropped 28.0% in 2022.
• Over 5 years, Accumulated Expenses stood at $8.5 million in 2018, then rose by 14.35% to $9.8 million in 2019, then retreated by 25.22% to $7.3 million in 2020, then soared by 68.75% to $12.3 million in 2021, then declined by 28.0% to $8.9 million in 2022.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $8.9 million, $12.3 million, and $7.3 million for Q4 2022, Q4 2021, and Q4 2020 respectively.